The KRITH bioengineering laboratory has created a micro-fabricated microdialysis device for quantitative drug susceptibility testing in Tuberculosis. For further information on this new development, click here.
Four Leslie Lab members received Keystone Symposium Global Health Travel Awards. They attended the conferences on Host Response in Tuberculosis and Granulomas in Infectious and Non-infectious diseases which took place in Santa Fe, New Mexico in January of this year. Click here for more information.
Professor Kelly Chibale, Professor of Organic Chemistry,DST/NRF South Africa Research (SARChI) Chair in Drug Discovery, was the guest speaker at the K-RITH Seminar Series in February. His presentation focused on H3-D: Pioneering Integrated Drug Discovery and Translational Medicine in Africa.
Dr. Schacker has developed an internationally recognized program in translational research focused on how HIV causes immune suppression. His group recently made the discovery of a process of inflammatory damage in lymphatic tissues;
Director of the Ragon Institute of MGH, MIT and Harvard, Bruce Walker, will be conducting a seminar with five guest speakers, who will be focusing on novel technologies for understanding the human immune response and in vaccine development.
Head of the University of the Witwatersrand node of the DST/NRF Centre of Excellence for Biomedical TB Research, Professor Bavesh Kana (PhD), will be hosting the next K-RITH Seminar Series. This Seminar Series will focus on the remodeling of mycobacterialpeptidoglycan during growth and tuberculosis disease.
Associate Professor, Muazzam Jacobs, will speak on 'Tumour Necrosis Factor Receptor (TNF-TNFR) interaction - a critical requirement for host immune protection against Mycobacterium tuberculosis infection' for the September K-RITH Seminar Series.